23rd Jun 2006 07:00
Pfizer to Return Indiplon Worldwide Rights to Neurocrine NEW YORK, June 23 -- Pfizer Inc said today it is returning to Neurocrine Biosciences, Inc. the development and marketing rights for Indiplon, a medicine in development to treat insomnia. This includes both the collaboration to develop and co-market Indiplon in the U.S. as well asPfizer's exclusive license to develop and market Indiplon outside of the U.S.SOURCE Pfizer Inc 06/23/2006 /CONTACT: Paul Fitzhenry of Pfizer Inc, +1-212-733-4637/ /Company News On-Call: Pfizer's press releases are available through PRNewswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html/ /Photo: A free corporate logo to accompany this story is available immediatelyvia Wieck Photo Database to any media with telephoto receiveror electronic darkroom, PC or Macintosh, that can accept overheadtransmissions. To retrieve a logo, please call 972-392-0888./ /Company News On-Call: http://www.prnewswire.com/comp/688250.html / /Web site: http://www.pfizer.com / (PFE)ENDPFIZER INCRelated Shares:
PFZ.L